The Company

Palo Alto Health Sciences, Inc. is a privately held Silicon Valley digital therapeutic company at the forefront of revolutionizing behavioral healthcare with evidence based, at-home, drug-free solutions. Our product, Freespira®, is an FDA-cleared treatment for individuals suffering from panic disorder, panic attacks and other symptoms of panic.

Our Mission

To improve the quality-of-life of people suffering from debilitating panic attacks associated with chronic behavioral and medical conditions; reducing medical costs and supporting the appropriate utilization of valuable healthcare resources.

Click to go to Newsroom

Leadership Team


Board of Directors

Russell Siegelman Chairman
Russell Siegelman has spent over twenty years in business and technology as a manager, investor and director. As a Lecturer at Stanford Business School he teaches Startup Garage, Product Launch and Starting and Growing a Social Venture. Starting in 1996, Russell spent eleven years as a Partner at Kleiner Perkins Caufield & Byers, where he invested in consumer and technology related technologies and markets, including software, electronic commerce, Web services, semiconductors, mobile systems, media and telecommunications.
Ned Scheetz
Ned Scheetz founded Aphelion Capital in 2005 and has over 20 years of healthcare investing experience. Prior to forming Aphelion, Ned was a Partner and Managing Director with Piper Jaffray Ventures (PJV), focusing on investments in emerging medical technology companies. Ned joined PJV from Janus Capital, where he was a Senior Research Analyst covering both healthcare and internet investments. Ned has served on numerous private company boards over his career. He currently serves on the Board of Directors for Aardvark Medical, ClearFlow, CyMedica, Explorer Surgical, Mercator Medsystems, and Palo Alto Health Sciences.
Amy Perry
Amy serves as CEO, Hospital Division, and Senior Vice President, Integrated Care Delivery, at Atlantic Health System, a $2.8 billion health care organization based in Morristown, New Jersey. Amy is a strategic leader with an impressive background in finance and operations, clinical quality and academic medicine, and health policy and governance. She has a strong track record of identifying opportunities for growth and innovation, as well as substantial experience improving outcomes, lowering costs, transitioning to value-based payments, and implementing population health strategies.
Debra Reisenthel
Debra is founding President and CEO of Palo Alto Health Sciences. Since joining PAHS in 2013, Debra has grown the company by establishing relationships with leading Payers and Employers while overseeing the development and launch of the next generation Freespira treatment for panic. She has led the programs to expand PAHS’ evidence base with clinical trials for PTSD and adolescents. In 2020, Debra was elected to the Board of Directors of Digital Therapeutics Alliance (DTA), the trade organization focused on advocating for digital therapeutics to payers, providers and regulatory agencies.

Key Clinical Leaders on Scientific Advisory Board

Mark Pollack, MD
Dr. Mark Pollack is The Grainger Professor and Chairman of the Department of Psychiatry at Rush University Medical Center. His areas of clinical and research interest include the acute and long-term course, pathophysiology and treatment of patients with anxiety disorders including panic disorder, social anxiety disorder, PTSD and generalized anxiety disorder and associated comorbidities, development of novel pharmacologic agents for mood and anxiety disorders, uses of combined cognitive-behavioral and pharmacologic therapies for treatment refractory patients, presentation and treatment of anxiety in the medical setting, and the pathophysiology and treatment of substance abuse. He has published over 300 articles, reviews and chapters, and is co-editor of the books “Challenges in Clinical Practice: Pharmacologic and Psychosocial Strategies”, “Panic Disorder and Its Treatment,” and “Social Phobia: Research and Practice” and “Ten Minute CBT”. Dr. Pollack lectures widely in national and international forum and serves on numerous editorial and advisory boards. He is Past President and on the Board of Directors of the Anxiety Disorders Association of America, and has served as Chairman of its Scientific Advisory Board. For more information, see here.
Stefan Hoffman, Ph.D.
Dr. Hofmann is Professor of Psychology at the Department of Psychological and Brain Sciences at Boston University. He is Director at PERL and his is research focuses on the mechanism of treatment change, translating discoveries from neuroscience into clinical applications, emotions, and cultural expressions of psychopathology. He is president of the Association for Behavioral and Cognitive Therapies, and the International Association for Cognitive Psychotherapy. He is also editor in chief of Cognitive Therapy and Research and is Associate Editor of Journal of Consulting and Clinical Psychology. He has published more than 300 peer-reviewed journal articles and 15 books. He is a Highly-Cited Researcher by Thomson Reuters, among many other awards. He is an expert on emotion and cognitive behavioral therapy. For more information, see here.
Simon Rego, PsyD
Dr. Rego is Chief Psychologist, Director of Psychology Training, and Director of the CBT Training Program at Montefiore Medical Center and Associate Professor of Clinical Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine. He is a member of the Board of Directors of the Association for Behavioral and Cognitive Therapies and Chair of the Public Education Committee for the New York State Psychological Association. He is Board Certified in Cognitive Behavioral Psychology by the American Board of Professional Psychology and Certified as a Cognitive Therapy Trainer/Consultant by the Academy of Cognitive Therapy. He is an Editorial Board member of numerous journals, has 30 publications and 140 professional presentations, and constantly works with the media in order to educate the public about the latest mental health news using a simple, non-sensationalized approach. For more information, see here.
Terence Keane, Ph.D.
Dr. Keane is Professor of Psychiatry and Clinical Psychology at Boston University. Assistant Dean of VA Research, Keane is also the Associate Chief of Staff for Research and Development at VA Boston Healthcare System and Director of the National Center for Posttraumatic Stress Disorder’s Behavioral Science Division. Dr. Keane has published fourteen edited volumes and over 300 articles and chapters on the assessment and treatment of PTSD. For the past 37 years the VA, the National Institutes of Health, Department of Defense, and Substance Abuse Mental Health Services Administration (SAMHSA) have continuously supported his program of research on psychological trauma. In 2015, Dr. Keane received the John Blair Barnwell Award for Outstanding Contributions in Clinical Science from the Veterans Health Administration. Dr. Keane is a Fellow of the American Psychological Association and the Association for Psychological Science. He has consulted, lectured, and conducted workshops internationally on topics related to psychological trauma. For more information, see here.

Business Advisors